Get the Stockscreener App
0.9363
0.31%
-0.0029
Allakos Inc stock is traded at $0.9363, with a volume of 24,773.
It is down -0.31% in the last 24 hours and up +9.73% over the past month.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
See More
Previous Close:
$0.9392
Open:
$0.9157
24h Volume:
24,773
Relative Volume:
0.04
Market Cap:
$92.87M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
-0.4851
EPS:
-1.93
Net Cash Flow:
$-139.92M
1W Performance:
-20.65%
1M Performance:
+9.73%
6M Performance:
-34.52%
1Y Performance:
-47.10%
1-Day Range:
$0.9022
$0.9393
1-Week Range:
$0.9022
$1.235
52-Week Range:
$0.535
$3.405
Allakos Inc Stock (ALLK) Company Profile
Name
Allakos Inc
Sector
Industry
Phone
650-597-5002
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Compare ALLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALLK | 0.9363 | 92.87M | 0 | -166.14M | -139.92M | -1.93 |
| VRTX | 446.01 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.16 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.51 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-17-24 | Downgrade | Jefferies | Buy → Hold |
| Jan-16-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-18-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-08-23 | Resumed | Jefferies | Buy |
| Sep-27-23 | Initiated | JMP Securities | Mkt Outperform |
| May-12-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-07-23 | Initiated | Piper Sandler | Overweight |
| Sep-12-22 | Downgrade | SMBC Nikko | Neutral → Underperform |
| Dec-22-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-21 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-22-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-22-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-15-21 | Initiated | Cowen | Outperform |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Feb-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | BofA Securities | Buy |
| Dec-21-20 | Initiated | SVB Leerink | Outperform |
| Feb-27-20 | Initiated | Barclays | Underweight |
| Feb-04-20 | Resumed | Goldman | Neutral |
| Aug-13-18 | Initiated | Goldman | Neutral |
| Aug-13-18 | Initiated | Jefferies | Buy |
| Aug-13-18 | Initiated | William Blair | Outperform |
View All
Allakos Inc Stock (ALLK) Latest News
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy - MSN
Allakos Inc. finalizes early lease termination, incurring $2.5 million in costs - Investing.com Canada
Allakos Inc. Alters Lease Agreement for Cost Savings - TipRanks
FMR LLC's Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Allakos's SWOT analysis: biotech firm's stock faces hurdles in CSU market - Investing.com
FY2024 EPS Estimates for Allakos Raised by Leerink Partnrs - MarketBeat
Allakos Runs Up Into A Near-Term Catalyst (NASDAQ:ALLK) - Seeking Alpha
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Allakos perks up after early-stage data for lead asset - MSN
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in October - MarketBeat
3 US Penny Stocks With Market Caps Larger Than $50M - Simply Wall St
Allakos Insiders Miss 24% Gain After Offloading Stock - Simply Wall St
Vernal Keratoconjunctivitis Market Growth to Accelerate - openPR
The Manufacturers Life Insurance Company Sells 2,148 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Short Interest in Custom Truck One Source, Inc. (NYSE:CTOS) Decreases By 5.5% - Defense World
Nasal Polyposis Market Size is Set for Rapid Growth as Innovative - openPR
Chronic Spontaneous Urticaria Market Forecasted to Surge - openPR
Jefferies downgrades Allakos Inc (ALLK) stock to a Hold - Knox Daily
Allakos Inc (ALLK)’s stock price range in the last year - US Post News
Investor’s Delight: Allakos Inc (ALLK) Closes Weak at 0.65, Down -1.14 - The Dwinnex
Allakos shares hold rating after trial update By Investing.com - Investing.com Australia
Piper Sandler maintains Overweight rating on Allakos shares By Investing.com - Investing.com Australia
TD Cowen Reiterates Hold Rating on Allakos Inc. (ALLK) - StreetInsider.com
Piper Sandler maintains Overweight rating on Allakos shares - Investing.com India
Allakos shares hold rating after trial update - Investing.com
Allakos stock gains on trial data for lead drug (NASDAQ:ALLK) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on Allakos Inc. (ALLK) - StreetInsider.com
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - ForexTV.com
Allakos reports positive results from AK006 Phase 1 study - Investing.com India
Allakos Progress Update on AK006 and Future Milestones - TipRanks
Allakos reports positive results from AK006 Phase 1 study By Investing.com - Investing.com UK
Allakos (ALLK) Reports Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - StreetInsider.com
SG Americas Securities LLC Grows Stake in Stellantis (NYSE:STLA) - Defense World
Vernal Keratoconjunctivitis Market to Show Remarkable Growth - openPR
Vernal Keratoconjunctivitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc - Barchart
Duff & Phelps Investment Management Co. Cuts Holdings in Enbridge Inc. (NYSE:ENB) - Defense World
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions - MSN
Wall Street SWOT: Allakos stock faces pivotal year as AK006 data looms - Investing.com
Allakos (NASDAQ:ALLK) Receives Market Outperform Rating from JMP Securities - MarketBeat
Leerink Partners analysts initates a Market perform rating for Align Technology, Inc. (ALGN) - Knox Daily
Defense Stock Soars on ‘Rare Move’ From the U.S. Army - Barron's
French InsurTech Alan raises $193m to bolster tech and growth in Belgium - FinTech Global
Allied Properties Real Estate Investment Trust (TSE:AP.UN) Price Target Increased to C$18.50 by Analysts at Canaccord Genuity Group - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - MarketBeat
Allogene Therapeutics Inc [ALLO] Stock bought by Insider Douglas Earl Martin for $78844.0 - Knox Daily
Alignment Healthcare (NASDAQ:ALHC) Shares Gap Down to $11.43 - Defense World
Investing in Alta Equipment Group Inc (ALTG): What You Must Know - Knox Daily
Allegion Stock: Is ALLE Outperforming The Industrials Sector? - Barchart
Allakos Inc Stock (ALLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):